BCL2 and cancer: NK cells effectively drive cancer cells toward mitochondrial apoptosis, and when combined with the BCL-2 inhibitor venetoclax, they synergistically enhance the killing of cancer cells both in vitro and in vivo while pre-activated NK cells have been shown to become resistant to venetoclax (80).